Endocrine Carcinoma — Trials

Endocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 574
Recruiting: 291
Ph III recruiting: 33
Growth YoY: +1.5%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (236)

clinicaltrialsPublishedShowing 101–150 of 364 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06095583	Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)	recruiting	Phase 3	756	Shanghai Junshi Bioscience Co., Ltd.OTHER	6	Jul 27, 2026	clinicaltrials
NCT07502300	A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)	recruiting	Phase 3	562	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY